Product Description
Mechanisms of Action: CAAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Histogen
Company Location: San Diego CA 92121
Company CEO: Steven J. Mento
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis|Hepatocellular Carcinoma|Type 1 Diabetes|Cholestasis|Hepatitis, Alcoholic|Hepatitis A|Liver Cirrhosis|Liver Cirrhosis, Alcoholic|Fatty Liver, Alcoholic|Hypertension, Portal|Liver Transplant|Non-alcoholic Steatohepatitis|Liver Diseases, Alcoholic|Hepatic Insufficiency|End Stage Liver Disease|Hepatitis, Chronic|Liver Failure, Acute|Acute-On-Chronic Liver Failure|Hepatitis C, Chronic
Phase 1: COVID-19|Kidney Diseases|Intestinal Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03462576 |
CON-EX-0217 | N/A |
Terminated |
Liver Cirrhosis |
2019-07-15 |
2022-12-21 |
Primary Endpoints|Treatments |
|
NCT03439189 |
NCT02960204 | N/A |
Completed |
Hypertension, Portal|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis|Liver Cirrhosis, Alcoholic|Hepatitis, Alcoholic |
2019-04-08 |
2022-12-21 |
Primary Endpoints|Treatments |
|
2012-004245-33 |
2012-004245-33 | N/A |
Completed |
Acute-On-Chronic Liver Failure|Liver Failure, Acute |
2015-01-29 |
2022-03-13 |
||
NCT04803227 |
EMR-COV-PR001 | P1 |
Terminated |
COVID-19 |
2021-05-28 |
69% |
2022-01-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT02121860 |
IDN-6556-08 | P1 |
Completed |
Intestinal Diseases |
2014-07-01 |
2019-03-20 |
Treatments |
|
NCT02039817 |
IDN-6556-05 | P1 |
Completed |
Kidney Diseases |
2014-04-01 |
2019-03-20 |
Treatments |
|
NCT03205345 |
ENCORE-LF | P2 |
Unknown status |
Liver Cirrhosis |
2019-08-01 |
45% |
2021-03-02 |
|
2015-004473-32 |
2015-004473-32 | P2 |
Completed |
Hepatitis, Alcoholic|Liver Cirrhosis|Hypertension, Portal|Non-alcoholic Steatohepatitis |
2019-04-08 |
2022-03-13 |
Treatments |
|
NCT02686762 |
ENCORE-NF | P2 |
Completed |
Liver Cirrhosis|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic |
2019-01-29 |
33% |
2019-08-21 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2015-004336-35 |
2015-004336-35 | P2 |
Completed |
Non-alcoholic Steatohepatitis|Liver Cirrhosis, Alcoholic|Hepatitis, Alcoholic |
2019-01-29 |
2022-03-13 |
Treatments |
|
NCT02960204 |
ENCORE-PH | P2 |
Completed |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Liver Cirrhosis, Alcoholic|Hypertension, Portal |
2018-10-02 |
44% |
2022-01-15 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments |
NCT04806750 |
IDN-6556-14 | P2 |
Completed |
Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Hypertension, Portal|Liver Cirrhosis, Alcoholic|Fatty Liver, Alcoholic |
2018-10-02 |
2021-03-20 |
||
NCT02138253 |
POLT-HCV-SVR | P2 |
Completed |
Liver Cirrhosis |
2018-02-15 |
2019-03-20 |
Treatments |
|
NCT01653899 |
Pro00024049 | P2 |
Completed |
Type 1 Diabetes |
2016-06-01 |
2019-03-19 |
Treatments |
|
NCT02230670 |
LC | P2 |
Completed |
Liver Cirrhosis |
2016-01-01 |
2019-03-20 |
Treatments |
|
NCT01912404 |
AH | P2 |
Terminated |
Hepatitis, Alcoholic|Hepatitis A |
2015-08-01 |
2019-03-19 |
Treatments |
|
NCT02230683 |
PH | P2 |
Completed |
Liver Cirrhosis|Hypertension, Portal |
2015-05-01 |
2019-03-20 |
Treatments |
|
NCT02077374 |
NAFLD | P2 |
Completed |
Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Liver Diseases, Alcoholic |
2015-03-01 |
2019-03-20 |
Treatments |
|
NCT01937130 |
IDN-6556-02 | P2 |
Terminated |
End Stage Liver Disease|Liver Cirrhosis, Alcoholic|Hepatitis, Chronic|Hepatitis, Alcoholic|Liver Failure, Acute|Acute-On-Chronic Liver Failure|Hepatic Insufficiency |
2015-01-01 |
2019-03-19 |
Treatments |
|
NCT00080236 |
CL-000006556-PRO-0006 | P2 |
Completed |
Cholestasis|Liver Transplant|Hepatitis|Hepatocellular Carcinoma |
2006-01-01 |
2019-03-21 |
Treatments |
|
NCT00088140 |
CL-000006556-PRO-0007 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2005-10-01 |
2019-03-21 |
Treatments |